GABA受体激动剂在干眼模型中对炎症反应的调节作用及对眼表修复的影响
Anti-Inflammatory and Promoting Ocular Surface Effects of GABAAR Agonists in DED Mice
DOI: 10.12677/ACM.2023.133555, PDF,   
作者: 张德馨, 周子微:青岛大学医学部,山东 青岛;青岛大学附属医院,山东 青岛;郑恒瑞, 王 谦*:青岛大学附属医院,山东 青岛
关键词: 蝇蕈醇干眼症抗炎Muscimol DED Anti-Inflammatory
摘要: 目的:观察GABA A型受体激动剂Muscimol对干眼模型鼠眼中TNF-α、IL-1β表达的调节作用及对眼表修复的影响。方法:选用SPF级雌性C57BL/6小鼠(7~8周龄),用3 mg/mL东莨菪碱溶液皮下注射,同时模拟干燥环境建立干眼症模型,14天后给予3 mg/mL Muscimol溶液结膜下注射。于1、3、5天行泪液分泌量测定及荧光素钠染色,同时制备眼表组织切片,采用苏木素–伊红染色法评估角膜组织形态学变化。分别采用PCR、ELISA方法检测小鼠结膜组织中TNF-α和IL-1β的mRNA及蛋白的表达。结果:在使用Muscimol处理后的第1、3天各项临床指标均有恢复趋势,第5天后的泪液分泌量显著增加(P < 0.01),角膜荧光素钠染色分级减轻(P < 0.01)。角膜组织切片的HE染色结果显示,Muscimol处理组角膜上皮规整,相应损伤有所减轻。Muscimol处理组TNF-α和IL-1β的mRNA及蛋白的表达均呈下降趋势,第5天差别具有统计学意义(均P < 0.01)。结论:Muscimol结膜下注射可抑制干眼模型小鼠结膜中炎症因子的表达,促进眼表损伤的修复。
Abstract: Objective: To investigate the regulation of GABA type A receptor agonist Muscimol to the expres-sions of TNF-α and IL-1β and the effect on ocular surface repair in mice dry eye models. Methods: Female C57BL/6mice (7~8 weeks) were injected subcutaneously with scopolamine solution (3 mg/mL) in a dry environment. After 14 days, the mice were injected subconjunctivally with Musci-mol solution (3 mg/mL). Tear secretion, fluorescein staining score, and HE staining were examined on the 1st, 3rd, 5th day. PCR and ELISA quantified the mRNA and protein expressions of TNF-α and IL-1β. Results: All the clinical indexes demonstrated a recovery trend after Muscimol treatment. Tear secretion increased significantly (P < 0.01), and fluorescein staining score decreased (P < 0.01) on the 5th day. HE staining showed that the corneal epithelium damage had repaired in the Musci-mol treated group. The mRNA and protein expressions of TNF-α and IL-1β in the Muscimol treated group decreased significantly (P < 0.01 for all) on the 5th day. Conclusion: The application of Mus-cimol can inhibit the expression of inflammatory factors in the conjunctiva of dry eye model mice, and promote the repair of ocular surface.
文章引用:张德馨, 周子微, 郑恒瑞, 王谦. GABA受体激动剂在干眼模型中对炎症反应的调节作用及对眼表修复的影响[J]. 临床医学进展, 2023, 13(3): 3875-3882. https://doi.org/10.12677/ACM.2023.133555

参考文献

[1] Pflugfelder, S.C., Solomon, A. and Stern, M.E. (2000) The Diagnosis and Management of Dry Eye—A Twen-ty-Five-Year Review. Cornea, 19, 644-649. [Google Scholar] [CrossRef] [PubMed]
[2] Smith, J.A., Albeitz, J., Begley, C., et al. (2007) The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye Workshop (2007). Ocular Surface, 5, 93-107. [Google Scholar] [CrossRef
[3] Yu, L.F., Yu, C.J., Dong, H., et al. (2021) Recent Develop-ments about the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms. Frontiers in Pharma-cology, 12, Article ID: 732887. [Google Scholar] [CrossRef] [PubMed]
[4] Hessen, M. and Akpek, E.K. (2014) Dry Eye: An Inflammatory Ocular Disease. Journal of Ophthalmic and Vision Research, 9, 240-250.
[5] Gupta, A., Sadeghi, P.B. and Akpek, E.K. (2009) Occult Thyroid Eye Disease in Patients Presenting with Dry Eye Symptoms. American Journal of Ophthalmology, 147, 919-923. [Google Scholar] [CrossRef] [PubMed]
[6] Dastjerdi, M.H., Hamrah, P. and Dana, R. (2009) High-Frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-Daily Regimen. Cornea, 28, 1091-1096. [Google Scholar] [CrossRef
[7] Ryu, E.H., Kim, J.M., Laddha, P.M., et al. (2012) Therapeu-tic Effect of 0.03% Tacrolimus Ointment for Ocular Graft versus Host Disease and Vernal Keratoconjunctivitis. Korean Journal of Ophthalmology, 26, 241-247. [Google Scholar] [CrossRef] [PubMed]
[8] Tam, P.M., Young, A.L., Cheng, L.L., et al. (2010) Topical 0.03% Tacrolimus Ointment in the Management of Ocular Surface Inflammation in Chronic GVHD. Bone Marrow Transplan-tation, 45, 957-958. [Google Scholar] [CrossRef] [PubMed]
[9] Tian, J., Chau, C., Hales, T.G., et al. (1999) GABA(A) Receptors Me-diate Inhibition of T Cell Responses. Journal of Neuroimmunology, 96, 21-28. [Google Scholar] [CrossRef
[10] Zhang, B.H., Vogelzang, A., Miyajima, M., et al. (2021) B Cell-Derived GABA Elicits IL-10(+) Macrophages to Limit Anti-Tumour Immunity. Nature, 599, 471. [Google Scholar] [CrossRef] [PubMed]
[11] Bhandage, A.K., Jin, Z., Korol, S.V., et al. (2018) GABA Reg-ulates Release of Inflammatory Cytokines from Peripheral Blood Mononuclear Cells and CD4(+) T Cells and Is Immu-nosuppressive in Type 1 Diabetes. Ebiomedicine, 30, 283-294. [Google Scholar] [CrossRef] [PubMed]
[12] Paul, A.M., Branton, W.G., Walsh, J.G., et al. (2014) GABA Transport and Neuroinflammation Are Coupled in Multiple Sclerosis: Regulation of the GABA Transporter-2 by Ganax-olone. Neuroscience, 273, 24-38. [Google Scholar] [CrossRef] [PubMed]
[13] Meng, J.X., Xin, X., Liu, Z., et al. (2016) Propofol Inhib-its T-Helper Cell Type-2 Differentiation by Inducing Apoptosis via Activating Gamma-Aminobutyric Acid Receptor. Journal of Surgical Research, 206, 442-450. [Google Scholar] [CrossRef] [PubMed]
[14] Tian, J., Dillion, B.J., Henley, J., et al. (2022) A GABA-Receptor Agonist Reduces Pneumonitis Severity, Viral Load, and Death Rate in SARS-CoV-2-Infected Mice. Frontiers in Immu-nology, 13, Article ID: 1007955. [Google Scholar] [CrossRef] [PubMed]
[15] Pflugfelder, S.C. and De Paiva, C.S. (2017) The Pathophysiol-ogy of Dry Eye Disease: What We Know and Future Directions for Research. Ophthalmology, 124, S4-s13. [Google Scholar] [CrossRef] [PubMed]
[16] Reins, R.Y., Lema, C., Courson, J., et al. (2018) MyD88 Defi-ciency Protects against Dry Eye-Induced Damage. Investigative Ophthalmology & Visual Science, 59, 2967-2976. [Google Scholar] [CrossRef] [PubMed]
[17] Schaumburg, C.S., Siemasko, K.F., De Paiva, C.S., et al. (2011) Ocular Surface APCs Are Necessary for Autoreactive T Cell-Mediated Experimental Autoimmune Lacrimal Keratoconjunctivitis. The Journal of Immunology, 187, 3653-3662. [Google Scholar] [CrossRef] [PubMed]
[18] Bandeen-Roche, K., Muñoz, B., Tielsch, J.M., et al. (1997) Self-Reported Assessment of Dry Eye in a Population-Based Setting. Investiga-tive Ophthalmology & Visual Science, 38, 2469-2475.
[19] Moss, S.E., Klein, R. and Klein, B.E. (2000) Prevalence of and Risk Factors for Dry Eye Syndrome. Archives of Ophthalmology, 118, 1264-1268. [Google Scholar] [CrossRef] [PubMed]
[20] Solomon, A., Dursun, D., Liu, Z., et al. (2001) Pro- and An-ti-Inflammatory Forms of Interleukin-1 in the Tear Fluid and Conjunctiva of Patients with Dry-Eye Disease. Investigative Ophthalmology & Visual Science, 42, 2283-2292.
[21] Pflugfelder, S.C., De Paiva, C.S., Tong, L., et al. (2005) Stress-Activated Protein Kinase Signaling Pathways in Dry Eye and Ocular Surface Disease. The Ocular Surface, 3, S154-S157. [Google Scholar] [CrossRef
[22] Xiang, Y.Y., Wang, S., Liu, M., et al. (2007) A GABAergic System in Airway Epithelium Is Essential for Mucus Overproduction in Asthma. Nature Medicine, 13, 862-867. [Google Scholar] [CrossRef] [PubMed]
[23] Rashid, S., Jin, Y., Ecoiffier, T., et al. (2008) Topical Omega-3 and Omega-6 Fatty Acids for Treatment of Dry Eye. Archives of ophthalmology, 126, 219-225. [Google Scholar] [CrossRef] [PubMed]
[24] Alam, S., Laughton, D.L., Walding, A., et al. (2006) Human Peripheral Blood Mononuclear Cells Express GABAA Receptor Subunits. Molecular Immunology, 43, 1432-1442. [Google Scholar] [CrossRef] [PubMed]
[25] Mendu, S.K., Bhandage, A., Jin, Z., et al. (2012) Different Subtypes of GABA-A Receptors Are Expressed in Human, Mouse and Rat T Lymphocytes. PLOS ONE, 7, e42959. [Google Scholar] [CrossRef] [PubMed]
[26] Prud’homme, G.J., Glinka, Y., Hasilo, C., et al. (2013) GABA Protects Human Islet Cells against the Deleterious Effects of Immunosuppressive Drugs and Exerts Immunoinhibitory Effects Alone. Transplantation, 96, 616-623. [Google Scholar] [CrossRef